Literature DB >> 8511777

Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes.

A Kretz-Rommel1, U A Boelsterli.   

Abstract

In a few patients diclofenac produces mild increases in serum aminotransferase activity and in rare cases may be associated with the occurrence of fulminant hepatic necrosis. Both direct toxic effects of a diclofenac metabolite and hypersensitivity reactions have been suggested as possible molecular mechanisms of liver injury. We investigated the pathways of bioactivation and cytotoxicity of diclofenac, which undergoes both aromatic hydroxylation and acyl glucuronidation, in short-term cultured rat hepatocytes. LDH release was first evident after 4 hr of incubation with diclofenac (> 500 microM). In addition, time- and concentration-dependent covalent binding of [14C]diclofenac to hepatocellular proteins occurred, indicating the presence of a reactive intermediate. To specifically explore the role of the acyl glucuronidation pathway in the induction of cytotoxicity and covalent drug-protein adducts, we used two inhibitors of the UDP-glucuronosyltransferase (UDPGT), borneol and 7,7,7-triphenylheptyl-UDP. LDH release was markedly increased in the presence of either UDPGT inhibitor. Alternatively, covalent binding to hepatocellular proteins was greatly reduced when the glucuronide formation was selectively blocked. Furthermore, in vitro inhibition of P450-dependent oxidative biotransformation with the selective inhibitor of the CYP2C subfamily sulfaphenazole or with cimetidine markedly reduced the extent of cytotoxicity, whereas the degree of covalent adduct formation remained unchanged. Similarly, pretreatment of the rats with phenobarbital (80 mg/kg/day for 4 days) delayed the onset and reduced the extent of diclofenac-induced LDH release. Collectively, these results indicate that the formation of a toxic diclofenac metabolite(s) catalyzed by P4502C in hepatocytes leads to acute lethal cell injury, whereas diclofenac acyl glucuronide formation is associated with covalent binding of a reactive metabolite to hepatocellular proteins that is not related to the acute cytotoxicity. The protein adduct formation and its modulation by UDPGT may, however, be toxicologically relevant for the expression of diclofenac hepatitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8511777     DOI: 10.1006/taap.1993.1097

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  14 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Multidrug Resistance-Associated Protein 3 Plays an Important Role in Protection against Acute Toxicity of Diclofenac.

Authors:  Renato J Scialis; Iván L Csanaky; Michael J Goedken; José E Manautou
Journal:  Drug Metab Dispos       Date:  2015-04-20       Impact factor: 3.922

3.  Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients.

Authors:  Thomas G Hammond; Xiaoli Meng; Rosalind E Jenkins; James L Maggs; Anahi Santoyo Castelazo; Sophie L Regan; Stuart N L Bennett; Caroline J Earnshaw; Guruprasad P Aithal; Ira Pande; J Gerry Kenna; Andrew V Stachulski; B Kevin Park; Dominic P Williams
Journal:  J Pharmacol Exp Ther       Date:  2014-06-05       Impact factor: 4.030

4.  Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics.

Authors:  Kyle S Saitta; Carmen Zhang; Kang Kwang Lee; Kazunori Fujimoto; Matthew R Redinbo; Urs A Boelsterli
Journal:  Xenobiotica       Date:  2013-07-05       Impact factor: 1.908

5.  Effects of dose, flow rate, and bile acid on diclofenac disposition in the perfused rat liver.

Authors:  Misato Uraki; Atsushi Kawase; Yuka Matsushima; Masahiro Iwaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-06       Impact factor: 2.441

Review 6.  Immediate-type hypersensitivity drug reactions.

Authors:  Shelley F Stone; Elizabeth J Phillips; Michael D Wiese; Robert J Heddle; Simon G A Brown
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

Review 7.  Drug-induced liver injury in older adults.

Authors:  Sarah J Mitchell; Sarah N Hilmer
Journal:  Ther Adv Drug Saf       Date:  2010-12

8.  Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model.

Authors:  A B Riemer; S Gruber; I Pali-Schöll; T Kinaciyan; E Untersmayr; E Jensen-Jarolim
Journal:  Clin Exp Allergy       Date:  2009-10-07       Impact factor: 5.018

9.  Involvement of Lysosomal Labilisation and Lysosomal/mitochondrial Cross-Talk in Diclofenac Induced Hepatotoxicity.

Authors:  Jalal Pourahmad; Yassar Mortada; Mohammad Reza Eskandari; Jafar Shahraki
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

10.  Immunogenomics reveal molecular circuits of diclofenac induced liver injury in mice.

Authors:  Eun-Hee Lee; Jung-Hwa Oh; Saravanakumar Selvaraj; Se-Myo Park; Mi-Sun Choi; Reinhard Spanel; Seokjoo Yoon; Jürgen Borlak
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.